Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial

202152 citationsJournal Articlebronze Open Access

Authors

Pyrotinib provided antitumor efficacy with a manageable safety profile in <i>HER2</i>-amplified patients with NSCLC.

Good health and well-being

Published in: Clinical Cancer Research

Volume 28, Issue 3, pp. 461-467

Field-Weighted Citation Impact: 5.73